<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE plist PUBLIC "-//Apple//DTD PLIST 1.0//EN" "http://www.apple.com/DTDs/PropertyList-1.0.dtd">
<plist version="1.0">
<dict>
	<key>ARVC</key>
	<dict>
		<key>SectionHeaders</key>
		<array>
			<string>I. Global/Regional Dysfunction and Structural Alterations</string>
			<string>II. Tissue Characterizations of Wall</string>
			<string>III. Repolarization Abnormalities</string>
			<string>IV. Depolarization and Conduction Abnormalities</string>
			<string>V. Arrhythmias</string>
			<string>VI. Family History</string>
		</array>
	</dict>
	<key>ARVC2010</key>
	<array>
		<array>
			<array>
				<string>2D Echo: Regional RV akinesia, dyskinesia, or aneurysm WITH PLAX RVOT ≥ 32 mm (PLAX/BSA ≥ 19 mm/m²) OR WITH PSAX RVOT ≥ 36 mm (PLAX/BSA ≥ 21 mm/m²) OR fractional area change ≤ 33%</string>
				<integer>100</integer>
			</array>
			<array>
				<string>MRI: Regional RV akinesia, dyskinesia, or aneurysm WITH ratio of RV EDV/BSA ≥110 mL/m² (male) or ≥ 100 mL/m² (female) OR RV EF ≤ 40%</string>
				<integer>100</integer>
			</array>
			<array>
				<string>RV Angiography: Regional RV akinesia, dyskinesia, or aneurysm</string>
				<integer>100</integer>
			</array>
			<array>
				<string>2D Echo: Regional RV akinesia, dyskinesia, or aneurysm WITH PLAX RVOT ≥ 29 to &lt; 32 mm (PLAX/BSA ≥ 16 to &gt; 19 mm/m²) OR WITH PSAX RVOT ≥ 32 to &lt; 36 mm (PLAX/BSA ≥ 18 to &lt; 21 mm/m²) OR fractional area change &gt; 33% and ≤ 40%</string>
				<integer>1</integer>
			</array>
			<array>
				<string>MRI: Regional RV akinesia, dyskinesia, or aneurysm with ratio of RV EDV/BSA ≥100 to &lt; 110 		mL/m² 		(male) or ≥ 90 to &lt; 100 mL/m² (female) OR RV EF &gt; 40% to ≤ 45%</string>
				<integer>1</integer>
			</array>
		</array>
		<array>
			<array>
				<string>Residual myocytes &lt; 60% by morphometric analysis (or &lt; 50% if estimated) with fibrous replacement of RV free wall myocardium in ≥ 1 sample, with or without fatty replacement of tissue on endomyocardial biopsy</string>
				<integer>100</integer>
			</array>
			<array>
				<string>Residual myocytes 60% to 70% by morphometric analysis (or 50% to 60% if estimated) with fibrous replacement of RV 		free wall myocardium in ≥ 1 sample, with or without fatty 	replacement of tissue on endomyocardial biopsy</string>
				<integer>1</integer>
			</array>
		</array>
		<array>
			<array>
				<string>T wave inversion (V1, V2, and V3) or beyond in individuals &gt; 14 yrs (in absence of complete RBBB)</string>
				<integer>100</integer>
			</array>
			<array>
				<string>T wave inversion in V1 and V2 in individuals &gt; 14 yrs (in absence of complete RBBB) or in V4, V5, V6</string>
				<integer>1</integer>
			</array>
			<array>
				<string>T wave inversion in V1-V4 in individuals &gt; 14 yrs in presence of complete RBBB</string>
				<integer>1</integer>
			</array>
		</array>
		<array>
			<array>
				<string>Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of T ave) in right precordial leads (V1-V3)</string>
				<integer>100</integer>
			</array>
			<array>
				<string>Late potentials on SAECG in absence of QRS duration ≥ 110 msec on standard ECG:  Filtered QRS duration ≥ 114 msec</string>
				<integer>1</integer>
			</array>
			<array>
				<string>Late potentials on SAECG in absence of QRS duration ≥ 110 msec on standard ECG:  Duration of terminal QRS &lt; 40 µV (low amplitude signal duration) ≥ 38 msec</string>
				<integer>1</integer>
			</array>
			<array>
				<string>Late potentials on SAECG in absence of QRS duration ≥ 110 msec on standard ECG:  Root-mean-square voltage of terminal 40 msec ≤ 20 µV</string>
				<integer>1</integer>
			</array>
			<array>
				<string>Terminal activation duration of QRS ≥ 55 msec measured from the nadir of the S wave to the end of the QRS including R&apos;, in V1, V2, or V3, in the absence of complete RBBB</string>
				<integer>1</integer>
			</array>
		</array>
		<array>
			<array>
				<string>Nonsustained or sustained VT of LBBB morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)</string>
				<integer>100</integer>
			</array>
			<array>
				<string>Nonsustained or sustained VT of RV outflow configuration, LBBB morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis</string>
				<integer>1</integer>
			</array>
			<array>
				<string>&gt; 500 ventricular extrasystoles per 24 hours (by Holter)</string>
				<integer>1</integer>
			</array>
		</array>
		<array>
			<array>
				<string>ARVC/D confirmed in a first-degree relative who meets current Task Force criteria</string>
				<integer>100</integer>
			</array>
			<array>
				<string>ARVC/D confirmed apthologically at autopsy or surgery in a first-degree relative</string>
				<integer>100</integer>
			</array>
			<array>
				<string>Identification of a pathogenic mutation categorized as associated or probably asoociated with ARC/D in the patient under evaluation</string>
				<integer>100</integer>
			</array>
			<array>
				<string>History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria</string>
				<integer>1</integer>
			</array>
			<array>
				<string>Premature sudden death (&lt; 35 years of age) due to suspected ARVC/D in a first-degree relative</string>
				<integer>1</integer>
			</array>
			<array>
				<string>ARVC/D confirmed pathologically or by current Task Force Cirteria in a second-degree relative</string>
				<integer>1</integer>
			</array>
		</array>
	</array>
</dict>
</plist>
